AKTSHealthcare
Aktis Oncology, Inc. Insider Trading Activity
Every SEC Form 4 insider transaction reported for Aktis Oncology, Inc. (AKTS), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud Research Team · SEC Form 4 & insider trading data analysts
Last updated:
Quick Answer
Are AKTS insiders buying or selling?
Aktis Oncology, Inc. insiders reported 6 open-market buys ($114.3M) and 3 sells ($2.9M) across 9 Form 4 filings — a net buying position of $111.5M.
Source: SEC EDGAR Form 4
Key Statistics (as of Jul 20, 2026)
Total Form 4 filings
9
SEC EDGAR
Insider filers
9
Insider buys (6)
$114.3M
Insider sells (3)
$2.9M
Insider sentiment
Net buyingNet insider flow of $111.5M in net buying.
Recent AKTS insider transactions
| Date | Insider | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jul 20, 2026 | Ken Herrmann | Director | Sale | 3.1K | $25.21 | $77.3K |
| Jul 10, 2026 | Shulamit Ron-Bigger | Chief Operating Officer | Sale | 50.0K | $27.75 | $1.4M |
| Jul 10, 2026 | Akos Czibere | Chief Medical Officer | Sale | 50.0K | $27.77 | $1.4M |
| Jan 14, 2026 | Todd Foley | Director, 10% Owner | Purchase | 232.9K | $18.00 | $4.2M |
| Jan 14, 2026 | Luke Evnin | 10% Owner | Purchase | 1.1M | $18.00 | $20.0M |
| Jan 14, 2026 | Ansbert Gadicke | 10% Owner | Purchase | 1.1M | $18.00 | $20.0M |
| Jan 13, 2026 | EcoR1 Capital, LLC | Director | Purchase | 2.2M | $18.00 | $40.0M |
| Jan 12, 2026 | Vida Ventures II, LLC | 10% Owner | Purchase | 835.0K | $18.00 | $15.0M |
| Jan 12, 2026 | Helen Susan Kim | Director, 10% Owner | Purchase | 835.0K | $18.00 | $15.0M |
Showing the 9 most recent of 9 Form 4 filings for Aktis Oncology, Inc..
Most active AKTS insiders
- Akos Czibere1 filing
- Ansbert Gadicke1 filing
- EcoR1 Capital, LLC1 filing
- Helen Susan Kim1 filing
- Ken Herrmann1 filing
Ask anything about AKTS insider activity
Use Trabud's AI agent to query Aktis Oncology, Inc.'s Form 4 history in plain English — "Show me AKTS CEO purchases this year" or compare it against any other ticker.
Open the AI agentAKTS insider trading FAQ
Are Aktis Oncology, Inc. insiders buying or selling?
Across 9 SEC Form 4 filings, Aktis Oncology, Inc. (AKTS) insiders reported 6 open-market purchases totaling $114.3M and 3 sales totaling $2.9M. That is a net buying position of $111.5M.
How many insiders trade AKTS stock?
9 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for Aktis Oncology, Inc.. The most recent filing was accepted on Jul 20, 2026.
Where does Trabud get AKTS insider trading data?
All AKTS insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.
Looking for another company? Browse all tracked companies.